Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?

Adapting the 0.01% NPM1/ABL1 cut-off, we observed the clearest separation of the cumulative incidence of relapse (CIR, p 

Saved in:
Bibliographic Details
Published in:HemaSphere 2024-03, Vol.8 (3), p.e55-n/a
Main Authors: Schwind, Sebastian, Bischof, Lara, Bill, Marius, Grimm, Juliane, Ussmann, Jule, Backhaus, Donata, Brauer, Dominic, Thanh, Tung Pham, Merz, Maximilian, Franke, Georg‐Nikolaus, Metzeler, Klaus H., Vucinic, Vladan, Herling, Marco, Platzbecker, Uwe, Jentzsch, Madlen
Format: Article
Language:English
Subjects:
Blood
Bone marrow
Chemotherapy
Graft versus host disease
Letter
Leukemia
Myeloid Malignancies
Patients
Remission (Medicine)
Stem cell transplantation
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adapting the 0.01% NPM1/ABL1 cut-off, we observed the clearest separation of the cumulative incidence of relapse (CIR, p 
ISSN:2572-9241
2572-9241
DOI:10.1002/hem3.55